FDA's NDA And BLA Approvals: Zejula, Ocrevus, Dupixent
Executive Summary
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.